Wednesday, June 18, 2025 6/18/2025

Development of Pirenzepine for CIPN

Award Number: R41CA213555
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/23/2017
PERIOD OF PERFORMANCE END DATE: 07/31/2018

Group Awards By:

View Award Description

Development of Pirenzepine for CIPN - PROJECT SUMMARY Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating complication that can arise from use of a number of chemotherapeutics, and which limits both the dose and duration of cancer treatments with these agents. Up to 40% of cancer patients treated with chemotherapy describe some form of CIPN, with sensory neuropathy being dominant. Symptoms vary from tingling and numbness indicative of sensory loss to aspects of painful neuropathy such as allodynia and spontaneous shooting pains. The American Society of Clinical Oncology makes no recommendations for the prevention of CIPN and provides only a moderate recommendation for treatment with duloxetine, a serotonin-norepinephrine reuptake inhibitor for symptomatic relief of pain. WinSanTor’s founders have uncovered a new homeostatic mechanism in sensory neurons that constrains mitochondrial function, which can be exploited to improve energy supply to reverse and to prevent nerve damage in CIPN. We have demonstrated that the muscarinic acetylcholine type 1 receptor (M1R) signaling limits mitochondrial activity and that antagonizing M1R increases the overall respiratory capacity of mitochondria. Additionally, we have observed that the M1R antagonist pirenzepine can prevent the neuropathy induced by chemotherapeutic agents. The goal of this Phase I STTR project is to assess the therapeutic potential of pirenzepine as a CIPN intervention that enhances neuronal AMPK activity and restores neuronal energy capacity to prevent or reverse neuropathy without impeding the chemotherapeutic microtubule-stabilizing properties of paclitaxel. To this end our Specific Aims are: Specific Aim 1. Assess the tumoricidal activity of paclitaxel in presence of pirenzepine. Specific Aim 2. Test efficacy of pirenzepine in mouse paclitaxel models of CIPN. The studies proposed herein will advance further pre-clinical development of pirenzepine as a potentially first- in-class therapy for preventing and/or reversing CIPN.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2019 ( Subtotal = $0 )
2019	2017	WINSANTOR, INC.	7220 TRADE ST STE 370	SAN DIEGO	CA	92121	SAN DIEGO	USA	Cancer Treatment Research	000	1	2/5/2019	NEW	$0
														Subtotal = $0

Issue Date FY: 2017 ( Subtotal = $298,550 )
2017	2017	WINSANTOR, INC.	6150 LUSK BLVD #B201	SAN DIEGO	CA	92121	SAN DIEGO	USA	Cancer Treatment Research	000	1	5/23/2017	NEW	$298,550
														Subtotal = $298,550

Grand Total All Awards = $298,550

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of Pirenzepine for CIPN

Award Number: R41CA213555

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/23/2017

PERIOD OF PERFORMANCE END DATE: 07/31/2018

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer